Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEB071 plus tacrolimus versus Myfortic plus tacrolimus in de novo renal transplant recipients
2005-003494-25Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sotrastaurin in kidney allograft rejection (3 arms), sponsored by Novartis. Primary endpoint: Primary efficacy failure at 6 months. Started May 2006; status: terminated.
02
Drugs
sotrastaurin
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2005-003494-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003494-25.